Kakao Ventures Makes Seed Investment in Medical AI Company 'DeepMetrix'

[Asia Economy Reporter Kang Nahum] Kakao's investment-specialized subsidiary Kakao Ventures announced on the 20th that it invested 1.5 billion KRW in DeepMetrics together with Shinhan Capital and IMM Investment. DeepMetrics is a company developing machine learning-based software for medical devices.

DeepMetrics, founded mainly by CEO Song Hyun-oh who worked at Google Research and IBM Research, consists of world-class researchers and medical experts. In addition, several researchers with outstanding capabilities in machine learning, including Professor Ko Young-il of the Hematology and Oncology Department at Seoul National University Hospital, have joined.

DeepMetrics possesses technology that estimates arterial blood pressure (ABP) from photoplethysmography (PPG) and classifies heart valve diseases. It also estimates arrhythmia and determines its severity using only electrocardiogram (ECG) or PPG data. Furthermore, it is developing AI models for therapeutic drug monitoring and ventilators.

The software for medical devices developed by DeepMetrics is a core element in modern specialized medical devices. High-priced specialized medical devices are complicated to operate in detail, and there are not enough specialists who can easily handle them. The development of software for medical devices is expected to assist medical professionals in their medical practices and greatly benefit patients.

Although it is an early-stage company, the positive outlook of the related market and top-level research achievements received favorable evaluations in this investment.

Kim Chi-won, Managing Director of Kakao Ventures, evaluated DeepMetrics as "a company with unique AI technology focused on biosignals" and said, "We expect it to open a new chapter in the medical AI market."

This content was produced with the assistance of AI translation services.